{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:08:31Z","timestamp":1780387711136,"version":"3.54.1"},"reference-count":48,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.3111\/13696998.2015.1132225","type":"journal-article","created":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T17:10:02Z","timestamp":1450199402000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma"],"prefix":"10.3111","volume":"19","author":[{"given":"Emily","family":"Nash Smyth","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Conti","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Wooldridge","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Bowman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ball","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,1,22]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481201900203"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3169"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-6-463"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2013.820959"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(11)70004-X"},{"key":"e_1_3_3_7_1","unstructured":"Cancer Facts & Figures 2013. Atlanta: American Cancer Society 2013. Available at: http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-036845.pdf [Last accessed 26 August 2015]"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70198-4"},{"key":"e_1_3_3_13_1","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen LS","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87","journal-title":"Cancer J"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"e_1_3_3_15_1","unstructured":"Zometa Prescribing Information. East Hanover: Novartis 2012. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021223s022lbl.pdf [Last accessed 11 March 2014]."},{"key":"e_1_3_3_16_1","unstructured":"Aredia Prescribing Information. East Hanover: Novartis 2010. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020036s039lbl.pdf[Last accessed 11 March 2014]."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0167"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.846"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmonc.2012.02.015"},{"key":"e_1_3_3_20_1","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage MJ","year":"2008","unstructured":"Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22","journal-title":"Am J Manag Care"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2010.16.9.693"},{"key":"e_1_3_3_22_1","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea T","year":"2006","unstructured":"Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7","journal-title":"J Support Oncol"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.890937"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm3030883"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.330"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-328"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1077-2"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2014.04.001"},{"key":"e_1_3_3_29_1","volume-title":"A systematic literature review of the economic burden in multiple myeloma. ISPOR 17th Annual European Congress","author":"Rizzo M","year":"2014","unstructured":"Rizzo M, Xu Y, Panjabi S, et al. A systematic literature review of the economic burden in multiple myeloma. ISPOR 17th Annual European Congress. November 8-12, 2014; Amsterdam, The Netherlands."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.4.5.565"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22678"},{"key":"e_1_3_3_32_1","volume-title":"Skeletal-related events in myeloma: A population-based study. 2013 American Society of Hematology (ASH) Annual Meeting and Exposition","author":"Ashcroft J","year":"2013","unstructured":"Ashcroft J, Timothy B, Smith A, et al. Skeletal-related events in myeloma: A population-based study. 2013 American Society of Hematology (ASH) Annual Meeting and Exposition. December 7-10, 2013; New Orleans, LA."},{"key":"e_1_3_3_33_1","volume-title":"Truven Health Analytics MarketScan Publication and Trademark Guidelines","author":"Truven Health Analytics","year":"2014","unstructured":"Truven Health Analytics. 2014 Truven Health Analytics MarketScan Publication and Trademark Guidelines; Ann Arbor, 2014."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1177013815"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0061"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1047"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.4065\/82.4.516"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2038"},{"key":"e_1_3_3_42_1","first-page":"148","article-title":"Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus","volume":"8","author":"Chandran A","year":"2015","unstructured":"Chandran A, Bonafede MK, Nigam S, et al. Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus. Am Health Drug Benefits 2015;8:148-58","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S76167"},{"key":"e_1_3_3_44_1","first-page":"e490","article-title":"Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes","volume":"20","author":"David G","year":"2014","unstructured":"David G, Gill M, Gunnarsson C, et al. Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes. Am J Manag Care 2014;20:e490-7","journal-title":"Am J Manag Care"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-116"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2434"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S55779"},{"key":"e_1_3_3_48_1","unstructured":"SEER Stat Fact Sheets: Myeloma. Surveillance Epidemiology and End Results Program. Bethesda: National Cancer Institute 2015. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html [Last accessed 11 March 2014]"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0113"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2015.1132225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:04:00Z","timestamp":1770397440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2015.1132225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,22]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.3111\/13696998.2015.1132225"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2015.1132225","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}